BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder of the follicular epithelium. OBJECTIVES: The objective of the present study was to evaluate the effectiveness of the combination of tetracycline with colchicine in the treatment of HS. METHODS: Twenty patients (10 women and 10 men) with HS were included in an open, prospective, pilot study. All patients were treated with 100 mg minocycline administered orally once per day in combination with 0.5 mg colchicine administered twice per day for 6 months followed by a maintenance regimen of 0.5 mg colchicine administered orally twice per day for 3 months. Patients were examined at baseline and thereafter every 3 months for a total of 9 months. The efficacy of the treatment was evaluated using a physician's global assessment (PGA) scale, the Hurley scoring system, and the Dermatology Life Quality Index (DLQI). RESULTS: A significant improvement in clinical manifestation was reflected in scores on the Hurley scoring system and DLQI. According to the PGA, patients achieved substantial improvement or complete remission. Clinically, all patients started to show signs of improvement within the first 3 months of therapy and continued to improve over the next 6 months. CONCLUSIONS: This study indicates that the combination of the anti-inflammatory actions of colchicine and minocycline is effective in disease control in HS. Colchicine emerged as a safe option for the maintenance of the obtained result.
BACKGROUND:Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder of the follicular epithelium. OBJECTIVES: The objective of the present study was to evaluate the effectiveness of the combination of tetracycline with colchicine in the treatment of HS. METHODS: Twenty patients (10 women and 10 men) with HS were included in an open, prospective, pilot study. All patients were treated with 100 mg minocycline administered orally once per day in combination with 0.5 mg colchicine administered twice per day for 6 months followed by a maintenance regimen of 0.5 mg colchicine administered orally twice per day for 3 months. Patients were examined at baseline and thereafter every 3 months for a total of 9 months. The efficacy of the treatment was evaluated using a physician's global assessment (PGA) scale, the Hurley scoring system, and the Dermatology Life Quality Index (DLQI). RESULTS: A significant improvement in clinical manifestation was reflected in scores on the Hurley scoring system and DLQI. According to the PGA, patients achieved substantial improvement or complete remission. Clinically, all patients started to show signs of improvement within the first 3 months of therapy and continued to improve over the next 6 months. CONCLUSIONS: This study indicates that the combination of the anti-inflammatory actions of colchicine and minocycline is effective in disease control in HS. Colchicine emerged as a safe option for the maintenance of the obtained result.
Authors: Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin Journal: J Am Acad Dermatol Date: 2019-03-11 Impact factor: 15.487
Authors: Robin Christensen; Berit L Heitmann; Karina Winther Andersen; Ole Haagen Nielsen; Signe Bek Sørensen; Mohamad Jawhara; Anette Bygum; Lone Hvid; Jakob Grauslund; Jimmi Wied; Henning Glerup; Ulrich Fredberg; Jan Alexander Villadsen; Søren Geill Kjær; Jan Fallingborg; Seyed A G R Moghadd; Torben Knudsen; Jacob Brodersen; Jesper Frøjk; Jens Frederik Dahlerup; Anders Bo Bojesen; Grith Lykke Sorensen; Steffen Thiel; Nils J Færgeman; Ivan Brandslund; Tue Bjerg Bennike; Allan Stensballe; Erik Berg Schmidt; Andre Franke; David Ellinghaus; Philip Rosenstiel; Jeroen Raes; Mette Boye; Lars Werner; Charlotte Lindgaard Nielsen; Heidi Lausten Munk; Anders Bathum Nexøe; Torkell Ellingsen; Uffe Holmskov; Jens Kjeldsen; Vibeke Andersen Journal: BMJ Open Date: 2018-02-08 Impact factor: 2.692
Authors: Stefano Dastoli; Steven Paul Nisticò; Pietro Morrone; Cataldo Patruno; Antonio Leo; Rita Citraro; Luca Gallelli; Emilio Russo; Giovambattista De Sarro; Luigi Bennardo Journal: Pharmaceutics Date: 2022-01-27 Impact factor: 6.321